| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Histochemistry,*
Imperial College
School of Medicine, Hammersmith Campus, London, United Kingdom; the
Cardiovascular Research Center,
Harvard
Medical School, Charlestown, Massachusetts; and the William
Harvey Research Institute,
St. Bartholomew’s
and Royal London School of Medicine and Dentistry, London,
United Kingdom
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, interleukin-1ß, and tumor necrosis
factor-
. The inducible NOS isoform is characterized by production of
persistent and high concentrations of NO.8
There is now ample evidence to indicate that expression and activity of
NOS isoforms are significant in osteoblast and osteoclast biology. NO
seems to have an overall suppressive effect on bone resorption
inhibiting both osteoclast activity and precursor recruitment and this
may be associated with iNOS activity.9-16
However,
constitutive eNOS activity may also be of consequence, stimulating
osteoclast function.9,16
Basal, constitutive NO synthesis
within osteoblasts supports proliferation and activity of these
cells.17
Moreover, osteoblast NO synthesis/activity is
augmented by osteogenic hormones such as estrogen18
and
involves up-regulation of eNOS.19
Stimulation of eNOS and
synthesis of NO by osteoblasts and osteocytes is also involved in
mediating the osteogenic effects induced in response to mechanical
strain or shear flow.20-24
Conversely, iNOS activity
(stimulated in response to interleukin-1ß, tumor necrosis factor-,
and interferon-) causes marked suppression of osteoblast
function.25-27
Numerous studies have also shown that
administration of NOS inhibitors to rats in vivo leads to a
reversible osteopenia.12,28,29
Rat models of
ovariectomy-induced osteopenia have also revealed that osteoporotic
bone loss can be alleviated by administration of NO donors and
conversely, inhibition of endogenous NO suppresses the bone-conserving
action of estradiol.18
These observations have demonstrated that the synthesis and activity of both eNOS and iNOS is significant in bone biology although there is consensus that under physiological conditions eNOS probably represents the major NOS activity regulating bone formation.17-24 Despite this, many of the previous studies have been based on the use of NOS inhibitors and are therefore subject to potential inconsistencies arising from the lack of isoform-specific selectivity of these compounds as well as effects independent of NOS inhibition.4,29 Consequently, it has not been previously possible to define clearly the contribution made by a specific NOS isoform to the control of bone turnover.
In this respect eNOS gene-deficient (eNOS-/-) mice30 and their wild-type controls (eNOS+/+) could be a useful model to study the contribution made by NO to the control of bone metabolism and bone regulation by circumventing the lack of isoform specificity of the current generation of NOS inhibitors. Moreover, this can provide useful information to test previous studies on this field based on pharmacological inhibition of this NO synthase. The aim of this study therefore, was to test the hypothesis that the eNOS isoform plays a major role in regulation of bone growth and remodeling and that disruption of the eNOS gene alters this process. Histomorphometry and dual energy X-ray absorptiometry (DEXA) was used to analyze the bones of young adult eNOS-/- and eNOS+/+ mice. We also performed in vitro studies on osteoblasts isolated from calvarial explants to further investigate the mechanism of action of eNOS.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
eNOS-/- mice and their respective wild-type controls were generated on a mixed SV129/C57BL/6 background by intercrossing heterozygous parents as described previously.30 In all experiments we used wild-type or heterozygous littermates as controls. Mice were viable, fertile, and indistinguishable from wild type and heterozygous littermates in gross physical appearance and routine behavior.
Reagents
Except where indicated all chemicals and reagents were obtained from Sigma-Aldrich, Poole, UK.
Genotyping
Mice from each litter were genotyped by polymerase chain reaction (PCR) to confirm presence or absence of the eNOS gene. Tail snips (3 mm) were taken from mice between 8 and 15 days of age under local anesthesia. Samples were placed in 0.4 ml of lysis buffer (10 mmol/L Tris, pH 8.0, 50 mmol/L ethylenediaminetetraacetic acid, 100 mmol/L NaCl, 0.5% sodium dodecyl sulfate, and 500 µl/ml proteinase K) at 55°C with agitation overnight. Lysate was then extracted once with phenol-chloroform (1:1) and chloroform, (1:1), respectively, by mixing gently six times and centrifugation for 10 minutes at 9,000 rpm. The DNA was precipitated by absolute ethanol (2:1), washed with 1 ml of 70% ethanol, and resuspended in 30 µl of distilled water. Amplification of DNA products was accomplished by subjecting 2 to 4 µl of resuspended DNA to 35 cycles of PCR (94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute) and then to one cycle of PCR (72°C for 10 minutes) in the presence of dNTPs (50 µmol/L) and 2.5 U of Taq polymerase (Promega, Madison, WI) in a standard buffer containing 1.8 mmol/L MgCl2. The sense oligonucleotide 5'-GGGCTCCCTCCTTCCGGCTGCCACC-3' and the antisense oligonucleotide 5'-GGATCCCTGGAAAAGGCGGTGAGG-3', which amplify a 900-bp PCR product of eNOS cDNA identified eNOS+/+ mice. In contrast, the sense oligonucleotide 5'-ATGAACTGCAGGACGAGGCAGCG-3' and the antisense 5'-GGCGATAGAAGGCGATGCGCTG-3', which amplify a 603-bp PCR product, corresponding to the neo resistance gene and therefore, identified eNOS-/- mice. For each experiment, positive and negative control samples were always run. The amplified products were electrophoresed in 1% agarose gel with 50 µl/ml ethidium bromide.
Histology
Mice were killed by cervical dislocation and lungs, heart, liver, kidneys, and spleen were removed and fixed in 10% buffered formalin. The long bones were also removed and processed as described below. Paraffin-embedded sections (4 µm) were cut and stained with hematoxylin and eosin (H&E).
Bone Histomorphometry
Static and dynamic bone histomorphometry was performed on the femurs from 22 eNOS-/- and 19 eNOS+/+ male mice. All mice were maintained in a temperature-controlled room (24°C) with free access to sterilized water and food. Mice were divided into the following groups: 1) 6 weeks old (six eNOS+/+ and eight eNOS-/- mice); 2) 9 weeks old (seven eNOS+/+ and six eNOS-/- mice); 3) 18 weeks old (six eNOS+/+ and eight eNOS-/- mice).
For the purposes of dynamic histomorphometry all mice were injected intraperitoneally with oxytetracycline (30 mg/kg body weight) and with calcein (30 mg/kg body weight) 9 and 3 days before killing, respectively.
Femurs were removed from each mouse immediately after killing. Soft tissues were gently excised and length of the bones recorded. Bones were cut with an electrical saw at the exact midshaft to facilitate bone marrow embedding. Fixation was performed immediately after collection by immersion in 70% ethanol for 48 hours at 4°C. The bones were then dehydrated in increasing concentrations of ethanol and embedded in methyl-methacrylate without decalcification.31-33 After polymerization of the resin, blocks were sectioned using a Reichert-Jung 1140 autocut (Leica UK Ltd., Milton Keynes, UK) equipped with a tungsten carbide-tipped Jung D profile knife (Leica UK Ltd.). Five 3-µm serial sections were cut, deplasticized with 2-methoxyethylacetate for 20 minutes, and stained with Von Kossa with toluidine blue at acid pH as counterstain31-33 for the static histomorphometry analysis. For dynamic histomorphometry two 12-µm sections from distal femur, neither deplasticized nor stained, were used to investigate fluorochrome labeling.
Histomorphometry of trabecular bone was made in longitudinal sections
of distal femur within an area between 500 to 2,700 µm from the
epiphyseal growth plate, to exclude the primary
spongiosa.31-33
Thirty-two to 40 fields were analyzed
from each distal femur metaphysis. Evaluation of bone turnover during
remodeling included static evaluation using serial sections for various
parameters and dynamic evaluation using fluorochrome labeling of bone
in situ. Stereology using a Merz grid was
performed.31-33
Table 1
shows the histomorphometric parameters used in this study. They
were reported according to the recommended American Society of Bone and
Mineral Research nomenclature.34
|
DEXA analysis was performed on female mice aged 8 weeks (seven eNOS-/- and seven eNOS+/+) and 12 weeks (seven eNOS-/- and seven eNOS+/+). The mice were maintained under conditions identical to those described above. Animals were killed by intraperitoneal overdose of pentabarbitone sodium (Euthatal; RMB Animal Health Ltd., UK). Total and regional (femur/pelvis and spine) bone mineral density was measured using a Lunar DPX bone densitometer (Lunar Corp., Madison, WI) and analysis performed using ultra-high resolution software designed for small animals.
In Vitro Studies
Culture of Primary Calvarial Osteoblasts
Primary mouse osteoblast-enriched cultures were isolated by
sequential enzymatic digestion of neonatal calvariae, as previously
described.35
Briefly, the calvariae were dissected from 25
neonatal eNOS+/+ and 25 eNOS-/- mice and digested with collagenase
for sequential periods of 2 x 10 minutes and 3 x 20
minutes. Cells isolated from the final three digests were then plated
into 75-cm2
flasks in -modified Eagle’s
medium with nucleotides supplemented with 15% v/v fetal calf serum, 10
mmol/L sodium ß-glycerophosphate, 50 µg/ml ascorbic acid, 50 U/ml
penicillin G, 50 µg/ml streptomycin, and 0.3 µg/ml amphotericin B.
After 24 hours cells were released by 0.25%
trypsin-ethylenediaminetetraacetic acid treatment, pooled, and then
plated into 24-well culture plates at a density of 5 x
103
cells/well forsubsequent assessment of
proliferation, alkaline phosphatase activity, and formation of
mineralized bone nodules.
Osteoblast Proliferation
Cells were plated into 24-well culture plates at a density of
5 x 103
cells/well and allowed to settle
overnight. Cells were then temporarily growth arrested by incubation
for 24 hours in -modified Eagle’s medium supplemented with 0.1%
serum. Thereafter cells were maintained for 5 days in full culture
media (with one change after 3 days), released by 0.25% v/v
trypsin-ethylenediaminetetraacetic acid treatment, and resuspended in
10% v/v fetal calf serum-containing media. After centrifugation
(1,000 x g x 5 minutes) cells were resuspended
in 10% v/v fetal calf serum-containing media mixed with 0.4% w/v
trypan blue in 1:1 ratio and a viable cell count performed using a
hemocytometer (nonviable cells were stained with trypan blue).
Osteoblast Differentiation
i) Alkaline Phosphatase Activity: Cells were plated into 24-well culture plates at a density of 5 x 103 cells/well and maintained in full culture media for 12 days (with fresh changes every 3 days). Total alkaline phosphatase enzyme activity was assessed as described previously.27 Briefly, total cellular protein was extracted by digestion in buffer containing 0.1% lauryl sulfate (SDS), 0.1% Nonidet P-40, 10 µl/ml phenylmethylsulfonyl fluoride, 30 µl/ml aprotinin, and 10 µl/ml sodium orthovanadate. Cell lysates were collected and either assayed immediately or stored at -20°C. To 50 µl of lysate, 50 µl of alkaline buffer solution and 50 µl of substrates were added. The mixture was incubated at 37°C for 30 minutes, and the reaction was then stopped by adding 100 µl of 0.5 mol/L NaOH and absorbance was read at 405 nm using a Multiscan RC plate reader (Labsystems, Life Sciences International Ltd., Hampshire, UK). A standard curve was constructed using p-nitrophenol as a standard concentration range (6.25 to 400 µmol/L) and alkaline phosphatase activity was calculated. One unit of activity is defined as the amount of enzyme activity that liberates 1 nmol of p-nitrophenol per minute under the assay conditions. The results were normalized for total protein concentration by the Bradford dye-binding method. The absorbance was read at 750 nm using a Multiscan RC plate reader against a protein standard curve generated using bovine serum albumin (0.2 to 10 mg/ml). Measurements were made from a total of nine replicates representing three separate experiments.
ii) Bone Nodule Assay: To assess the ability of osteoblasts to express their mature phenotype the bone nodule assay was performed, which is a well-established quantitative assay of in vitro bone formation.35 Cells were grown in 4-cm wells for 21 days with an initial seeding density of 5 x 104 cells/well, in which the media was changed every 3 days. Cultures were fixed in 10% v/v formol saline for 5 minutes. Mineralized bone nodules were detected by Alizarin Red (pH 7.4) staining. Bone nodules per well were counted macroscopically.
Osteoblast Response to 17ß-Estradiol
For 48 hours before experimentation, cultures of eNOS+/+ and
eNOS-/- osteoblasts were maintained in 0.1% v/v serum and phenol
red-free -modified Eagle’s medium supplemented with
antibiotics/antimycotics. After 48 hours the cells were placed in
phenol red-free -modified Eagle’s medium supplemented with 10% v/v
dextran-charcoal stripped fetal bovine serum and
antibiotics/antimycotics. Osteoblasts were dose-dependently treated
with 17ß-E2 (10-10 to
10-6 mol/L; data not shown). A final
concentration of 10-7 mol/L was used in all
experiments. Cell proliferation in response to 17ß-estradiol was
assessed as described above. Cells were also treated with the inactive
stereoisomer 17-estradiol (17-E2,
10-7 mol/L; data not shown).
Response to S-Nitrosoacetylpenicillamine (SNAP)
To assess the effects of exogenous application of NO on osteoblast proliferation and differentiation, osteoblasts from eNOS-/- and eNOS+/+ were dose-dependently treated with SNAP (0.01 to 50 µmol/L; data not shown). A final concentration of 1 µm SNAP was used in all experiments. SNAP was replenished each time the cells were fed and its effects on proliferation, alkaline phosphatase activity, and bone nodule formation was assessed as described above.
Chemotaxis Assay
Chemotactic responses were measured by a modified Boyden Chamber
assay36
using 6-well Transwell chambers (Costar U.K. Ltd.,
High Wycombe, UK) that is divided by polycarbonate filters with 8-µm
pores. Media was added to both the lower and upper chambers and left
for 30 minutes to equilibrate. Then 3 x 103
cells/well were placed in the upper chamber and left for 2 hours to
attach. Transforming growth factor-ß1 (10 ng/ml, 1 ng/ml, 100
g/ml) was added to the lower chamber and left for 4 hours. The
filter was immersed in alcohol (4°C) to fix the cells. The cells on
the upper aspect of the filter were carefully removed by scraping with
the edge of a glass coverslip, and then the filter was rinsed in 0.05
mol/L Tris buffer (pH 9). The filter was then stained with a
DNA-binding fluorescent reagent 4,6-diamidino-2-phenylindole, enabling
visualization and direct counting of cell nuclei, of cells that had
migrated across the filter, by fluorescent microscopy (Olympus BX60
photomicroscope). Data presented as percentage increase relative to
control, unstimulated cells.
Statistical Methods
Results of the static and dynamic histomorphometry and cell culture experiments were expressed as the mean and SEM. Cell culture experiments were performed in triplicate and repeated four times. Differences between eNOS-/- and eNOS+/+ mice were determined by statistical analysis using Student’s t-test or by analysis of variance. A value of P < 0.05 was taken as a significant difference.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
An example of genotyping eNOS-/- and eNOS+/+ mice by PCR is
shown in Figure 1
. The set of primers (A)
that amplified a 900-bp PCR product identified eNOS+/+ mice. The set of
primers (B) that amplified a 603-bp PCR product identified eNOS-/-
mice.
|
Histological examination of eNOS-/- mice organs revealed no
pathological findings or abnormalities except for a mild glomerular
hypercellularity observed in 
10% of 9-week-old eNOS-/- mice.
Bone Histomorphometry
Results of measurements made in distal femur metaphyses of
eNOS-/- and eNOS+/+ mice are shown in Table 2
. Gross measurements made on the femur
revealed that eNOS-/- mice had a significant reduction in femur
length at 6 (P < 0.01), 9
(P < 0.05), and 18 (P <
0.05) weeks of age (Table 2)
.
|
and
Figures 2 and 3
).
There was also a significant reduction in mean trabecular thickness at
6 weeks of age (Table 2)
. Osteoid surface (OS/BS) decreased from
12.61 ± 1.4% in eNOS+/+ mice to 8.17 ± 0.8% in eNOS-/-
mice (P < 0.05) at 6 weeks of age (Table 2)
.
Osteoblast surface (Ob.S/BS) was also decreased from 7.8 ± 1.4%
in the femurs of 6-week-old eNOS+/+ mice to 4.4 ± 0.5%
(P < 0.05) in age-matched eNOS-/- mice (Table 2)
. Analysis of the eroded surface (ES/BS) showed that there was a
reduction from 2.90 ± 0.42% observed in the femurs of 6-week-old
eNOS+/+ mice to 1.44 ± 0.14% (P < 0.05)
in eNOS-/- mice (Table 2)
; however, there were no significant
differences in the osteoclast surface (Table 2)
.
|
|
. Mineral apposition rate (MAR) showed a modest decrease
from 1.75 ± 0.09 to 1.52 ± 0.060 µm/day
(P < 0.05) in the femurs of 6-week-old eNOS +/+
and eNOS-/- mice, respectively (Table 2)
. Bone formation rate fell in
the femurs of both 6-week-old (0.4 ± 0.03 to 0.2 ± 0.02
µm3/µm2/day;
P < 0.01) and 9-week-old (0.22 ± 0.01 to
0.13 ± 0.02
µm3/µm2/day;
P < 0.05) eNOS-/- mice compared to wild-type mice.
Histomorphometric analysis of femurs from 18-week-old animals revealed
a significant reduction in mean trabecular thickness decreasing from
43.30 ± 2.06 µm to 37.57 ± 1.36 µm
(P < 0.05) in eNOS-/- mice. All other
parameters were found not to be significantly different from wild-type
mice (Table 2
, Figure 4
).
|
Analysis of 8-week-old eNOS+/+ and eNOS-/- female mice revealed
a significant reduction in both femoral/pelvic and spinal bone mineral
density (Figure 5)
decreasing from
0.1650 ± 0.0029 g/cm2
to 0.154 ±
0.0023 g/cm2
(P < 0.05)
and from 0.167 ± 0.0041 to 0.150 ± 0.0044
g/cm2
(P < 0.01),
respectively. Analysis of total bone mineral density of whole body was
also significantly reduced decreasing from 0.223 ± 0.0022 to
0.217 ± 0.0028 g/cm2
(P < 0.05). Analysis of 12-week-old mice showed
no significant differences in bone mineral density between eNOS+/+ and
eNOS-/- mice.
|
After 5 days in culture, cell counts (Figure 6a)
showed that there was a significantly
greater number of eNOS+/+ osteoblasts (10.87 ± 0.597 x
104
cells) compared to eNOS-/- osteoblasts
(4.032 ± 0.368 x 104
cells)
(P < 0.001). Analysis of alkaline phosphatase
activity after 12 days in culture revealed (Figure 6b)
that this was
significantly lower in eNOS-/- osteoblasts (5.8 ± 0.399 U/mg
protein) compared to wild type (7.9 ± 0.150 U/mg protein;
P < 0.05). Osteoblasts from eNOS-/- mice formed
significantly fewer mineralized bone nodules (33 ± 9) compared to
eNOS+/+ (98 ± 14; P < 0.01) (Figure 7, A and B)
. In all experiments the reduction
in cell numbers, alkaline phosphatase activity, and bone nodule numbers
seen in eNOS-/- osteoblasts could be restored to values seen in wild
type by exogenous administration of SNAP (Figures 6 and 7)
.
|
|
.
|
In response to a transforming growth factor-ß gradient eNOS+/+
there was a significant increase in the proportion of cells that had
migrated across the polycarbonate filter toward increasing
concentrations of the cytokine. This response was attenuated in
eNOS-/- osteoblasts and there was no evidence of significant numbers
of cells that had migrated across the filter (Figure 9)
.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this study we have used an established eNOS gene-deficient mouse
model and their wild-type counterparts30
to investigate
parameters of bone remodeling and skeletal integrity under normal
physiological conditions. Initially we used bone histomorphometry to
show that eNOS gene-deficient mice had marked bone abnormalities with
significant reductions in bone formation rates and bone volume
confirming that eNOS is fundamental to the physiological regulation of
bone turnover. The histomorphometry data also implicated osteoblast
dysfunction as a significant cause of these abnormalities. This was
suggested by marked differences in surface estimates of new bone matrix
synthesis, mineralizing activity, and accretion rate of new bone, which
were all significantly lower in the eNOS-/- mice compared to eNOS+/+
mice. In part, this was found to be related to there being
significantly fewer osteoblasts lining trabecular bone surfaces with a
44% reduction in surface coverage in eNOS-/- mice suggesting
impaired recruitment and/or attachment to bone resorption sites.
Concordant alterations in tissue-level parameters of bone remodeling
were also evident. In particular, bone formation rate was decreased by
52 and 41% in eNOS-/- mice, compared to eNOS+/+ mice at 6 and 9
weeks of age, respectively. Consequently, with less bone being laid
down femoral bone volume was reduced by 28 and 45% in 6- and
9-week-old eNOS gene knockout mice, respectively.
This altered pattern of bone remodeling was found to be age-dependent and by 12–18 weeks of age, which corresponds to the period of peak bone mass, bone histomorphometry parameters were primarily restored to wild-type levels. This suggests that the consequences of eNOS gene deficiency are most pronounced in the rapidly growing, neonatal and adolescent skeleton. Regardless of eNOS expression the histomorphometry data show significantly higher bone turnover and higher bone remodeling activity in young adult mice compared to older animals. Similar findings have also been reported in rats and humans demonstrating that remodeling activity is related to skeletal maturation.33 In addition, we have previously shown that eNOS expression in rat femur is developmentally regulated and is most abundant in the bones of neonates and young adults and decreases markedly in older animals. From these data it is possible to suggest that eNOS expression is more abundant in younger animals and correlates to the higher bone metabolism and bone cell activity at these stages. Therefore as demonstrated in our histomorphometry studies lack of eNOS gene produced a higher impact in bone remodeling and turnover in pubescent young adult stages rather than in older adult mice.
How eNOS deficiency leads to these bone abnormalities is not altogether certain but on the basis of the histomorphometry data osteoblast dysfunction is implicated as a primary cause. We therefore sought to investigate the possible mechanism of impaired osteoblast function using a well-established in vitro model of osteoblast growth and differentiation.35,38 Primary cultures of neonatal calvarial osteoblasts revealed marked disruption to the control of osteoblast proliferation and differentiation with both parameters being retarded significantly compared to wild-type osteoblasts. Importantly, such studies also showed that impaired osteoblast proliferation and differentiation could be reversed by the NO donor SNAP indicating that the disrupted function was related directly to loss of NO-dependent signaling and not a generalized effect. The importance of the eNOS-NO pathway was also demonstrated by the finding that eNOS-/- osteoblasts were unresponsive to the mitogenic effects of 17ß-estradiol serving to confirm that NO-dependent signaling is important in mediating the effects of osteogenic factors such as estrogen.18,19 We also found that eNOS-/- osteoblasts had an attenuated chemotaxis response and failed to migrate along a transforming growth factor-ß gradient, which is known to be a potent cytokine in recruiting osteoblasts to remodeling sites.36
Taken together, these data indicate that distinct components of the osteoblast phase of the bone remodeling cycle are altered in the eNOS-/- mice. The replacement of resorbed bone and the quality of the bone laid down during the remodeling process depend on a number of parameters. These include the spatially and temporally co-ordinated proliferation, recruitment, and differentiation of osteoblasts at resorption sites, the subsequent synthesis and maturation of bone matrix proteins and also by the overall life span of the osteoblast.1-3 Our data demonstrate that NO-dependent signaling via eNOS is important in regulating several aspects of osteoblast biology including growth, differentiation, recruitment, and extracellular matrix synthesis. Although not specifically addressed in the present study the effects of eNOS gene deficiency will probably also impact on other important aspects of osteoblast biology. In particular, the eNOS-NO pathway is involved in mediating anabolic processes associated with mechanical loading and shear flow.20-24 Other cellular signaling pathways that are likely to be directly affected by loss of an intact eNOS-NO pathway include those involving cGMP and cGMP-dependent protein kinase II that are known to be associated with the control of osteoblast replication39 and bone growth.40 Integrin expression and function are also known to regulated by eNOS/NO41 and this may also affect osteoblasts in eNOS-/- mice, as integrins are crucial to osteoblast recruitment and differentiation42 and are also involved in mediating mechanical loading signals.43
The eNOS-/- mice were also found to have a slight (1 to 2 mm) reduction in femur length compared to wild-type mice. Although gross examination indicated there were no obvious differences in overall size or abnormalities in growth plate development (data not shown) between wild-type and knockout mice it is possible, based on the femur length that eNOS is associated with the control of skeletal growth. This would be in keeping with our recent work demonstrating that eNOS expression in rat bones is most abundant during the period of rapid growth from the neonatal to juvenile/young adult stages.44 Moreover, Gregg and colleagues,45 have described, in a separate eNOS knockout mouse model, a 10% incidence of limb reduction defects, although this was attributed more to malformation of limb capillaries.
The nature of the bone abnormalities observed using histomorphometry was also corroborated by DEXA analyses. These revealed significant reductions in regional bone mineral density including femur/pelvis and spine and also in total, whole-body bone mineral density. The DEXA analysis was performed specifically on female mice as a means to corroborate the bone abnormalities seen in males and to confirm that there were no marked differences associated with gender. Although a full comparative histomorphometric analysis of both male and female mice has yet to be performed the DEXA studies do at least suggest that there are no gross differences associated with gender in generating the abnormal bone phenotype expressed by eNOS-/- mice.
In addition to the osteoblast, NO is known to influence the function of the osteoclast.9-16 In this study, eroded surface, which is an indicator of osteoclast activity,31-33 was decreased by up to 50% in femora of 6-week-old eNOS-/- mice. In the absence of significant differences in osteoclast numbers between eNOS+/+ and eNOS-/- mice, this might indicate that eNOS is involved in the control of osteoclast activity and is supported by studies showing that osteoclasts contain eNOS and constitutive (eNOS) activity might be required to stimulate osteoclast activity.9,16 However, it would seem that by comparison to the effects on osteoblast function and bone formation the overall impact of eNOS gene deficiency on the osteoclast and bone resorption is less important. Indeed, by 9 and 18 weeks of age there were no significant differences in eroded surface or osteoclast number. Such a phenomenon would also be in general agreement with the study of Corral and colleagues46 demonstrating that bone resorption can proceed normally even after ablation of mature osteoblasts and in the absence of any new bone formation. Moreover, most studies have suggested that iNOS is probably more important in the control of osteoclast function.9-16 This is also strongly supported by observations on iNOS knockout mice showing that control of osteoclast function and bone resorption in response to stimulation with cytokines is significantly disrupted.47
Endothelial NOS gene knockout mice are also known to be hypertensive with an approximate 30% elevation in mean arterial blood pressure30 that could also have an affect on bone turnover. Studies in rats and humans have demonstrated a correlation between the incidence of high blood pressure and increased risk of osteoporosis48,49 and is thus possible that hypertension associated with eNOS deficiency might be a contributory factor to the genesis of bone abnormalities. Although this needs to be investigated in more detail there is good evidence to suggest that the major underlying cause of disrupted control of bone turnover is in fact related directly to loss of eNOS in the local bone environment rather than to a more global affect on blood pressure. For example, there is a substantial body of evidence to indicate that eNOS is expressed by osteoblasts/osteocytes23,24,50 and is significant in mediating the local, anabolic actions of estrogen18,19 as well as transducing the osteogenic effects associated with mechanical loading and shear flow.20-24 The present study also provides in vivo and in vitro evidence of distinct perturbations to osteoblast growth, differentiation, and function in eNOS-/- mice. Furthermore, chronic administration of certain NOS inhibitors in adult rats significantly diminishes bone formation, independent of any marked affect on blood pressure.12,29 Although such studies have tended to suggest that this was attributable more to inhibition of iNOS12,29 than eNOS the compounds used are not sufficiently selective in their action to be able to state unequivocally which isoform(s) are involved.37
Previous studies on NOS gene knockout mice have indicated that in certain tissues other NOS isoforms can substitute for the function of the disrupted one.51 This is based on the absence of expected disrupted function within a particular cell or tissue of a NOS gene knockout animal, which can be subsequently revealed after administration of a NOS inhibitor. The use of NOS inhibitors has not been investigated in the study. Although this could reveal the potential contributions made by other NOS isoforms the fact that eNOS-/- mice do exhibit marked bone abnormalities suggests any contribution from either iNOS or nNOS is minimal. As such, these data support the consensus that eNOS represents the predominant NOS activity in control of local bone remodeling and in the development and maintenance of skeletal mass.
On the basis of nature of their bone abnormalities eNOS-/- mice might also prove to be a useful model to investigate mechanisms of metabolic bone turnover and the development of diseases such as osteoporosis in which NO is known to be involved.18,52 However, by comparison to other osteoporosis-like phenotype models eNOS-/- mice are distinct. For example, osteoprotegerin-gene-deficient mice demonstrate an early onset osteoporosis-like phenotype,53 similar to eNOS-/- mice but is because of increased osteoclast numbers and resorption rather than attenuated osteoblast activity. Moreover, studies in mice overexpressing transforming growth factor-ß are known to express an osteoporotic phenotype primarily because of perturbation of osteoblast activity, but unlike eNOS-/- mice this phenotype is not expressed by adolescent mice but develops with increasing age.54 The finding that eNOS-/- mice recover from the early onset osteoporosis-like phenotype after 3 to 4 months represents another relevant difference between this and other osteoporosis-like phenotype models. As discussed above, eNOS gene-deficiency seems to specifically retard osteoblastic activity and the consequences of this become most manifest during periods of rapid bone turnover as seen in the postnatal development of the skeleton. The consequences of pathological disruption to bone turnover such as estrogen-deplete osteoporosis have not been investigated in the present study but it would be reasonable to suggest that because of the reduced responsiveness of their osteoblasts eNOS-/- mice are likely to be rendered more sensitive to such endocrine imbalance. This may also result in defective or protracted bone repair mechanisms.
In summary, we have investigated the impact of eNOS gene deletion on the murine skeleton under normal physiological conditions. The data show that eNOS is involved in the postnatal regulation of bone mass and lack of eNOS gene results in reduced bone volume and bone formation. The data also suggest that these bone abnormalities are attributable primarily to the impaired osteoblast function and identify eNOS as a significant regulator of local bone formation and turnover.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by project grants awarded by The Wellcome Trust, the Dunhill Medical Trust, and by generous donations from the Golden Charitable Trust.
J. A. and L. B. contributed equally to this work.
Accepted for publication October 19, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  V. W.T. Liu and P. L. Huang Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice Cardiovasc Res, January 1, 2008; 77(1): 19 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yano, T. Yamaguchi, I. Kanazawa, N. Ogawa, K. Hayashi, M. Yamauchi, and T. Sugimoto The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3160 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Robinson, M. Chatterjee-Kishore, P. J. Yaworsky, D. M. Cullen, W. Zhao, C. Li, Y. Kharode, L. Sauter, P. Babij, E. L. Brown, et al. Wnt/beta-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone J. Biol. Chem., October 20, 2006; 281(42): 31720 - 31728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grassi, X. Fan, J. Rahnert, M. N. Weitzmann, R. Pacifici, M. S. Nanes, and J. Rubin Bone Re/Modeling Is More Dynamic in the Endothelial Nitric Oxide Synthase(-/-) Mouse Endocrinology, September 1, 2006; 147(9): 4392 - 4399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zaragoza, E. Lopez-Rivera, C. Garcia-Rama, M. Saura, A. Martinez-Ruiz, T. R. Lizarbe, F. Martin-de-Lara, and S. Lamas Cbfa-1 mediates nitric oxide regulation of MMP-13 in osteoblasts. J. Cell Sci., May 1, 2006; 119(Pt 9): 1896 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhao, S. Zhuang, Y. Chen, G. R. Boss, and R. B. Pilz Cyclic GMP-dependent Protein Kinase Regulates CCAAT Enhancer-binding Protein {beta} Functions through Inhibition of Glycogen Synthase Kinase-3 J. Biol. Chem., September 23, 2005; 280(38): 32683 - 32692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hamerman Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies QJM, July 1, 2005; 98(7): 467 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aicher, A. M. Zeiher, and S. Dimmeler Mobilizing Endothelial Progenitor Cells Hypertension, March 1, 2005; 45(3): 321 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. van't Hof, J. MacPhee, H. Libouban, M. H. Helfrich, and S. H. Ralston Regulation of Bone Mass and Bone Turnover by Neuronal Nitric Oxide Synthase Endocrinology, November 1, 2004; 145(11): 5068 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qia |
